Johnson & Johnson (JNJ)
167.03
+2.66 (1.62%)
NYSE · Last Trade: Jul 22nd, 3:20 PM EDT
Detailed Quote
Previous Close | 164.36 |
---|---|
Open | 165.00 |
Bid | 167.03 |
Ask | 167.06 |
Day's Range | 164.71 - 167.33 |
52 Week Range | 140.68 - 169.99 |
Volume | 5,109,410 |
Market Cap | 439.06B |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | 5.200 (3.11%) |
1 Month Average Volume | 8,610,564 |
Chart
About Johnson & Johnson (JNJ)
Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More
News & Press Releases
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.
Via Benzinga · July 22, 2025
Apple expands retail presence in Saudi Arabia by launching online store and app, offering personalized support and localized experience.
Via Benzinga · July 22, 2025
Via FinancialNewsMedia · July 22, 2025
Three dividend-paying stocks with high yields present an opportunity for significant passive income but a potentially high dividend payout ratio.
Via MarketBeat · July 21, 2025
These S&P 500 dividend stocks have fallen by up to 33% and are best buys now.
Via The Motley Fool · July 20, 2025
Wall Street rose to new heights during the week amid strong earnings and solid economic data. Meanwhile, Fed rate cut debate heats up.
Via Benzinga · July 18, 2025
This week's M&A news includes strategic pivots and stumbles galore, with updates from WK Kellogg, Matador Restaurant and Windsurf.
Via Benzinga · July 18, 2025
Shares of Johnson & Johnson broke out of a classic ascending triangle pattern. They have since stalled out at resistance.
Via Benzinga · July 17, 2025
Three dividend stocks stand out in July, offering reliable income, attractive yields, and strong fundamentals to help investors navigate market volatility
Via MarketBeat · July 17, 2025
Johnson & Johnson earnings came in 3% higher than consensus. The company's operating leverage was "slightly diluted by higher tax."
Via Benzinga · July 17, 2025
Via Benzinga · July 17, 2025
Investors monitor shifting market dynamics and consumer behavior post-pandemic, with Sarat Sethi sticking with Johnson & Johnson amid a positive earnings report. Stephen Weiss picks iShares Bitcoin Trust ETF and Joseph Terranova chooses Intercontinental Exchange, with Piper Sandler raising price target for ICE. Johnson & Johnson's FY2025 earnings guidance rose, while iShares Bitcoin Trust ETF and Intercontinental Exchange shares saw varied movement.
Via Benzinga · July 17, 2025
Via The Motley Fool · July 17, 2025
Johnson & Johnson hinted at leveraging tariff delays to maintain its outlook; however, Jim Cramer credited the performance to lower tariffs.
Via Benzinga · July 17, 2025
Powell Panic, Pharma Power & a PEW Parade: Wall Street’s Wild Wednesday
Via Chartmill · July 17, 2025
Analysts highlighted momentum in oncology and MedTech, with Wells Fargo calling the second-half growth acceleration “achievable” and Morgan Stanley noting visibility risks from drug pricing and tariff policy.
Via Stocktwits · July 16, 2025
U.S. stocks moved higher today, with the Dow Jones gaining more than 200 points, or 0.5%, to close at 44,254.78.
Via Benzinga · July 16, 2025
Via The Motley Fool · July 16, 2025
Johnson & Johnson is back in rally mode after years of post-pandemic normalization and the impact of repositioning, set up to sustain higher prices for years.
Via MarketBeat · July 16, 2025